Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET/CT in Interstitial Lung Disease
NCT07817563Phase 1Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga FAPI-46 in interstitial lung disease (ILD), sponsored by Mayo Clinic. Primary endpoints: Maximum Standardized Uptake Value in Abnormal Lung Parenchyma at 1 hour and Maximum Standardized Uptake Value in Normal Lung Parenchyma at 1 hour. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07817563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817563.